tbuckley/cabot-search huggingface dataset:
Coffee Consumption and Colorectal Cancer Prognosis—Reply
Authors: Chen Yuan, Christopher Mackintosh, Kimmie Ng
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Abstract 11099: Use of Glycoprotein IIb/IIIa Inhibition in Prevention of Blalock- Taussig Shunt Thrombosis in Pediatric Cardiac Surgery
Authors: Breanna L Piekarski, Jenna Rogers, David Zurakowski, Sitaram M Emani
Journal: Circulation (2019)

Introduction: Morbidity and mortality related to thrombosis of modified Blalock-Taussig shunts (mBTS) remain a significant risk. Platelet inhibition following mBTS is known to reduce the risk of th...
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: Marijo Bilusic, Sheri McMahon, Ravi A Madan, Fatima Karzai, Yo-Ting Tsai, Renee N Donahue, Claudia Palena, Caroline Jochems, Jennifer L Marté, Charalampos Floudas, Julius Strauss, Jason Redman, Houssein Abdul Sater, Shahrooz Rabizadeh, Patrick Soon-Shiong, Jeffrey Schlom, James L Gulley
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1–, E2b–] targeting three TAAs—prostate-specific antigen (PSA), brachyury, and MUC-1—has been developed. Both brachyury and the C-terminus of MUC-1 are overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and have been shown to play an important role in resistance to chemotherapy, epithelial–mesenchymal transition, and metastasis. The transgenes for PSA, brachyury, and MUC-1 all contain epitope modifications for the expression of CD8+ T-cell enhancer agonist epitopes. We report here the first-in-human trial of this vaccine platform. Methods Patients with mCRPC were given concurrently three vaccines targeting PSA, brachyury, and MUC-1 at 5×10 11 viral particles (VP) each, subcutaneously every 3 weeks for a maximum of three doses (dose de-escalation cohort), followed by a booster vaccine every 8 weeks for 1 year (dose-expansion cohort only). The primary objective was to determine the safety and the recommended phase II dose. Immune assays and clinical responses were evaluated. Results Eighteen patients with mCRPC were enrolled between July 2018 and September 2019 and received at least one vaccination. Median PSA was 25.58 ng/mL (range, 0.65–1006 ng/mL). The vaccine was tolerable and safe, and no grade &gt;3 treatment-related adverse events or dose-limiting toxicities (DLTs) were observed. One patient had a partial response, while five patients had confirmed PSA decline and five had stable disease for &gt;6 months. Median progression-free survival was 22 weeks (95% CI: 19.1 to 34). Seventeen (100%) of 17 patients mounted T-cell responses to at least one TAA, whereras 8 (47%) of 17 patients mounted immune responses to all three TAAs. Multifunctional T-cell responses to PSA, MUC-1, and brachyury were also detected after vaccination in the majority of the patients. Conclusions Ad5 PSA/MUC-1/brachyury vaccine is well tolerated. The primary end points were met and there were no DLTs. The recommended phase II dose is 5×10 11 VP. The vaccine demonstrated clinical activity, including one partial response and confirmed PSA responses in five patients. Three patients with prolonged PSA responses received palliative radiation therapy. Further research is needed to evaluate the clinical benefit and immunogenicity of this vaccine in combination with other immuno-oncology agents and/or palliative radiation therapy. Trial registration number NCT03481816 .
Delaying the second dose of covid-19 vaccines
Authors: Dominic Pimenta, Christian Yates, Christina Pagel, Deepti Gurdasani
Journal: BMJ (2021)

On 30 December 2020, the UK announced a deviation from the recommended protocol for the Pfizer-BioNTech covid-19 vaccine, prolonging the interval between doses from 3 to 12 weeks. 1 2Similar decisions were made for the Oxford-AstraZeneca vaccine, for which a longer gap between doses had been shown to improve efficacy in some age groups. 3 The stated intention was to maximise benefit with limited supplies and to minimise hospital admissions and deaths.For the Pfizer-BioNTech vaccine, the decision to delay the second dose was based on extrapolations from phase III trial data showing an efficacy of 89% 15-21 days after the first dose. 4 5At the time, Pfizer did not support the decision, stating that high efficacy could not be guaranteed.
Case 9-2021: A 16-Year-Old Boy with Headache, Abdominal Pain, and Hypertension
Authors: Kristian R. Olson, Katherine Nimkin, Ryan W. Carroll, Nikolas Stathatos, Zehra Ordulu
Journal: New England Journal of Medicine (2021)

A 16-year-old boy presented with headache, nausea, vomiting, and abdominal pain. He had been injured 17 months earlier in an ATV accident and again 2 months later while playing soccer. Since then, episodic headache had occurred. On evaluation, the pulse was 160 beats per minute, and the blood pressure 239/162 mm Hg. A diagnosis was made.
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Authors: Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Carmelo Carlo-Stella, Fritz C. Offner, Anna Sureda, Gilles Salles, Joaquín Martínez-Lopez, Michael Crump, Denise N. Thomas, Peter N. Morcos, Cristiano Ferlini, Ann-Marie E. Bröske, Anton Belousov, Marina Bacac, Natalie Dimier, David J. Carlile, Linda Lundberg, David Perez-Callejo, Pablo Umaña, Tom Moore, Martin Weisser, Michael J. Dickinson
Journal: Journal of Clinical Oncology (2021)

Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. This phase I study evaluated glofitamab in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Data for single-agent glofitamab, with obinutuzumab pretreatment (
Failure to achieve global vaccine equity will have dire consequences
Authors: Andrew Goldstein
Journal: BMJ (2021)

I appreciate Hurley’s call for internationally equitable vaccination, which makes a clear case on the grounds of both altruism and self-interest.1 Many rich and powerful countries are donating vaccine doses through Covax. But these doses—in the order of hundreds of millions—are too little and too slow.

With a global population of 7.7 billion people, vaccine acquired herd immunity is likely to require at least 12 billion doses. Current production estimates put us …
CLO21-028: Clinical Outcomes for Advanced Hepatocellular Carcinoma Patients Treated With Systemic Agents in Real-World Practice
Authors: Karine Tawagi, Diana Maslov, Madhav KC, Danny Markabawi, Suresh Mukkamala, Fady Farag, Helen Yuan, Adi Bamnolker, Rula Saeed, Zoe Blake, Marc Matrana, Daniel Johnson
Journal: Journal of the National Comprehensive Cancer Network (2021)
COVID-19 in Primary and Secondary School Settings During the First Semester of School Reopening — Florida, August–December 2020
Authors: Timothy Doyle, Katherine Kendrick, Thomas Troelstrup, Megan Gumke, Jerri Edwards, Shay Chapman, Randy Propper, Scott A. Rivkees, Carina Blackmore
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

COVID-19 school-related cases among Florida students correlated with community incidence in the counties observed, and was highest in smaller counties, districts without mask requirements, and those that reopened earliest.
PHASE II STUDY COMPARING ACCELERATED TWICE DAILY AND ONCE DAILY THORACIC RADIOTHERAPY IN PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) TREATED CONCURRENTLY WITH CHEMOTHERAPY
Authors: C. E. Lee, P. Lorigan, F. Blackhall, P. Taylor, L. F. Ashcroft, N. Thatcher, C. Faivre-Finn
Journal: Journal of Thoracic Oncology (2010)
Abstract 15100: Ergonovine Provocation Testing With Echocardiographic Monitoring of Left Ventricular Wall Motion for Non-Invasive Diagnosis of Coronary Vasospasm: Safety and Clinical Usefulness
Authors: Sang Yong Om, Sang-Yong Yoo, Goo-Yeong Cho, Minsoo Kim, Sahmin Lee, Dae-Hee Kim, Jong-Min Song, Duk-Hyun Kang, Sang Sig Cheong, Seong-Wook Park, Seung-jung Park, Jae-kwan Song
Journal: Circulation (2019)

Background: We sought to evaluate the role of ergonovine provocation testing with echocardiographic monitoring of ventricular wall motion for non-invasive diagnosis of coronary vasospasm (CVS). Met...
Role of Physical Activity and Cardiac Rehabilitation in Patients Undergoing Hematopoietic Stem Cell Transplantation
Authors: Divyanshu Mohananey, Alexandra Sarau, Rohit Kumar, David Lewandowski, Sol M. Abreu-Sosa, Sunita Nathan, Tochukwu M. Okwuosa
Journal: JACC CardioOncology (2021)

Hematopoietic stem cell transplantation (HSCT) is a standard treatment for several malignancies, and >50,000 HSCT are performed annually worldwide. As survival after HSCT improves, cardiovascular disease and associated risk factors have gained importance as a significant cause of morbidity and mortality in this cohort. In this article, we detail the risk factors for cardiovascular disease and their impact in patients undergoing HSCT. Additionally, we critically review the data on the impact of physical exercise in patients undergoing HSCT. Although limited by significant heterogeneity in methodologies, small sample sizes, attrition, and lack of long-term cardiovascular follow-up, most of these studies reinforce the beneficial effects of physical activity and exercise in this patient population. Cardiac rehabilitation (CR) is a structured exercise and lifestyle modification program that is typically instituted in patients who experience acute cardiovascular events. We review the data on CR in the oncologic and nononcologic populations with an aim of building a framework for use of CR in HSCT patients.
Dynamics of Adaptation During Three Years of Evolution Under Long-Term Stationary Phase
Authors: Sophia Katz, Sarit Avrani, Meitar Yavneh, Sabrin Hilau, Jonathan Gross, Ruth Hershberg
Journal: Molecular Biology and Evolution (2021)

Many bacterial species that cannot sporulate, such as the model bacterium Escherichia coli, can nevertheless survive for years, following exhaustion of external resources, in a state termed long-term stationary phase (LTSP). Here we describe the dynamics of E. coli adaptation during the first three years spent under LTSP. We show that during this time, E. coli continuously adapts genetically through the accumulation of mutations. For nonmutator clones, the majority of mutations accumulated appear to be adaptive under LTSP, reflected in an extremely convergent pattern of mutation accumulation. Despite the rapid and convergent manner in which populations adapt under LTSP, they continue to harbor extensive genetic variation. The dynamics of evolution of mutation rates under LTSP are particularly interesting. The emergence of mutators affects overall mutation accumulation rates as well as the mutational spectra and the ultimate spectrum of adaptive alleles acquired under LTSP. With time, mutators can evolve even higher mutation rates through the acquisition of additional mutation rate-enhancing mutations. Different mutator and nonmutator clones within a single population and time point can display extreme variation in their mutation rates, resulting in differences in both the dynamics of adaptation and their associated deleterious burdens. Despite these differences, clones that vary greatly in their mutation rates tend to coexist within their populations for many years, under LTSP.
Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound
Authors: Ferga C Gleeson, Patricio Jeraldo, Michael J Levy, Stephen J Murphy, Helena Mendes-Soares, Giannoula Karagouga, Alexa F Mccune, Ana Garcia Garcia Deparedes, Benjamin R Kipp, Stephanie D Song, Sahil Khanna, Darrell S Pardi, Nicholas Chia
Journal: Gut (2021)

The objective of this systematic review and meta-analysis is to examine which work-related risk factors are associated with specific soft tissue shoulder disorders. We searched the electronic databases of Medline and Embase for articles published between 2009 and 24 March 2016 and included the references of a systematic review performed for the period before 2009. Primary cross-sectional and longitudinal studies were included when outcome data were described in terms of clinically assessed soft tissue shoulder disorders and at least two levels of work-related exposure were mentioned (exposed vs less or non-exposed). Two authors independently selected studies, extracted data and assessed study quality. For longitudinal studies, we performed meta-analyses and used GRADE (Grades of Recommendations, Assessment, Development and Evaluation) to assess the evidence for the associations between risk factors and the onset of shoulder disorders. Twenty-seven studies met the inclusion criteria. In total, 16 300 patients with specific soft tissue shoulder disorders from a population of 2 413 722 workers from Denmark, Finland, France, Germany and Poland were included in the meta-analysis of one case–control and six prospective cohort studies. This meta-analysis revealed moderate evidence for associations between shoulder disorders and arm-hand elevation (OR=1.9, 95% CI 1.47 to 2.47) and shoulder load (OR=2.0, 95% CI 1.90 to 2.10) and low to very low evidence for hand force exertion (OR=1.5, 95% CI 1.25 to 1.87), hand-arm vibration (OR=1.3, 95% CI 1.01 to 1.77), psychosocial job demands (OR=1.1, 95% CI 1.01 to 1.25) and working together with temporary workers (OR=2.2, 95% CI 1.2 to 4.2). Low-quality evidence for no associations was found for arm repetition, social support, decision latitude, job control and job security. Moderate evidence was found that arm-hand elevation and shoulder load double the risk of specific shoulder disorders. Low to very-low-quality evidence was found for an association between hand force exertion, hand-arm vibration, psychosocial job demands and working together with temporary workers and the incidence of specific shoulder disorders.
P09.28 Access to Intermediate and Intensive Care for Patients With Lung Cancer During the COVID-19 Period
Authors: T. Gorría, L. Fernández-Mañas, E. Auclin, R. Reyes, R. Lopez Castro, M. García De Herreros, C. Cruz, M. Viladot, L. Ghiglione, E. Seguí, J. Ramírez, C. Teixidó, M. Sánchez, C. Agustí, M. Boada, M.G. Antelo, P. Castro, A. Prat, N. Viñolas, N. Reguart, L. Mezquita
Journal: Journal of Thoracic Oncology (2021)
Utility of under-gel endoscopic mucosal resection with partial submucosal injection for a laterally spreading tumor
Authors: Kazuki Yamamoto, Naoki Kanomata, Takashi Ikeya
Journal: Endoscopy (2021)

Conventional endoscopic mucosal resection (EMR) is a widely used technique in the treatment of colorectal tumors. When resecting laterally spreading tumors (LSTs) with conventional EMR, the distal edge is difficult to dissect and tends to be piecemealed. However, the nongranular pseudodepressed type (LST-NG-PD) has a high risk of malignancy, requiring en bloc resection [1]. Endoscopic submucosal dissection (ESD) can ensure high en bloc resection rates, but it also has drawbacks such as high perforation rates, high cost, and long procedure times. Binmoeller et al. introduced underwater EMR (UEMR) as a useful alternative to ESD for LSTs [2]; however, treating the distal end remains a challenge and could cause segmental resection. In addition, the use of water in UEMR may impair clarity of view if bleeding occurs. Partial submucosal injection improves visualization of the distal edge [3], and gel immersion improves the endoscopic visual field [4] [5]. Here, we report that under-gel EMR with partial submucosal injection is an effective means of achieving en bloc resection of LST-NG-PD ([Video 1]).
P86.07 CDK12 Mutated Extensive Stage Small Cell Lung Cancer Showed an Exceptional Response to Olaparib and Paclitaxel
Authors: J.Y. Hwang, W.K. Hur, W. Bae, J. Choi, C. Low, E. Vagia, Y.K. Chae
Journal: Journal of Thoracic Oncology (2021)
P15.04 A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer
Authors: J. Riess, K. Schalper, K. Kelly, M. Shimoda, G. Luxardi, A. Merleev, A. Monjazeb, K. Danenberg, E. Maverakis, D. Gandara
Journal: Journal of Thoracic Oncology (2021)

KRAS mutant NSCLC is heterogeneous with differential responses to MEK inhibition and immune checkpoint blockade that may be dependent on: KRAS amino acid substitution, associated co-mutations, smoking status, and tumor mutational burden. Preclinical models suggest sequencing of MEK inhibitor before or after PD-1 blockade differentially modulate the immune microenvironment, impacting anti-tumor activity of PD-1 blockade. This phase 1 study examined intercalated sequencing schemes of the MEK inhibitor trametinib and the PD-1 antibody pembrolizumab with planned dose expansion in KRAS mutant NSCLC.
Abstract 15329: The CADILLAC Risk Score Outperforms the TIMI Risk Score in Accurately Identifying Patients at Low Risk for In-hospital Mortality and Adverse Cardiovascular Events Following ST-Elevation Myocardial Infarction
Authors: Peter Malamas, Sumeet Lall, Brent Dembo, Ninad Zaman, Brandon Peterson, Ryan Wilson
Journal: Circulation (2020)

The CADILLAC and TIMI risk scores have been used to predict events following revascularization following STEMI. Utilizing these scores may help to identify patients at low risk for mortality and major adverse cardiac events (MACE) following STEMI. We aimed to compare the prognostic accuracy of CADILLAC and TIMI risk scores for identifying patients with low risk for mortality and MACE. Retrospective review at a tertiary medical center of patients presenting with STEMI from 2014-2018, excluding those who presented with cardiogenic shock, cardiac arrest, or need for mechanical circulatory support. MACE was defined as sustained ventricular arrhythmias, ACS, CHF, and stroke. Low risk patient (CADILLAC 0-2, TIMI 0-1) outcomes were compared to high risk (CADILLAC&gt;2, TIMI&gt;1) using chi square, ROC, and logistic regression analyses. The study includes 341 patients. In hospital CADILLAC score for low risk patients had significantly lower event rate compared to high risk (4.7% vs. 11.7%, odds ratio = 0.37, 95% CI 0.16-0.85, p= 0.028). In hospital TIMI score comparing low vs. high risk patients showed no difference (8.3% vs. 7.2%, odds ratio= 1.18, 95% CI 0.39 - 3.59, p= 0.48). ROC curve predicting event rate showed CADILLAC (C=0.66, odds ratio 1.18; 95% CI 1.04 - 1.33; p=0.0064) vs. TIMI (C= 0.57, odds ratio 1.20; 95% CI 0.98 - 1.46; p=0.071). Evaluating 30 day and 1 year follow up, CADILLAC better predicted event rates vs. TIMI (Figure 1). Logistic regression for CADILLAC at 1 year shows significant association with event rates independent of parameters comprising either risk score (odds ratio 1.29; 95% CI 1.07 - 1.57; p=0.011) while TIMI does not (odds ratio 1.21; 95% CI 0.93 - 1.56; p=0.16). In conclusion, patients defined as low risk by CADILLAC following STEMI have significantly reduced in-hospital event rates. Utilizing this scoring system may help to guide feasibility of early hospital discharge. CADILLAC outperforms TIMI in its prognostic ability both in-hospital and follow ups.
P09.11 Nutritional Risk Status Predicts Overall Survival of Mexican Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
Authors: S. Campos-Gomez, J.J. Valdéz-Andrade, J. Esquivel-Gutierrez, E. Jaimes Alpizar, G. Pacheco-Cuellar, K. Campos-Gomez
Journal: Journal of Thoracic Oncology (2021)
Deficits in Advance Care Planning for Patients With Decompensated Cirrhosis at Liver Transplant Centers
Authors: Arpan Arun Patel, Gery W. Ryan, Diana Tisnado, Emmeline Chuang, Anne M. Walling, Sammy Saab, Saro Khemichian, Vinay Sundaram, Robert H. Brook, Neil S. Wenger
Journal: JAMA Internal Medicine (2021)

The burden of end-of-life care for patients with cirrhosis is increasing in the US, and most of these patients, many of whom are not candidates for liver transplant, die in institutions receiving aggressive care. Advance care planning (ACP) has been associated with improved end-of-life outcomes for patients with other chronic illnesses, but it has not been well-characterized in patients with decompensated cirrhosis.To describe the experience of ACP in patients with decompensated cirrhosis at liver transplant centers.For this multicenter qualitative study, face-to-face semistructured interviews were conducted between July 1, 2017, and May 30, 2018, with clinicians and patients with decompensated cirrhosis at 3 high-volume transplant centers in California. Patient participants were adults and had a diagnosis of cirrhosis, at least 1 portal hypertension-related complication, and current or previous Model for End-Stage Liver Disease with sodium score of 15 or higher. Clinician participants were health care professionals who provided care during the illness trajectory.Experiences with ACP reported by patients and clinicians. Participants were asked about the context, behaviors, thoughts, and decisions concerning elements of ACP, such as prognosis, health care preferences, values and goals, surrogate decision-making, and documentation.The study included 42 patients (mean [SD] age, 58.2 [11.2] years; 28 men [67%]) and 46 clinicians (13 hepatologists [28%], 11 transplant coordinators [24%], 9 hepatobiliary surgeons [20%], 6 social workers [13%], 5 hepatology nurse practitioners [11%], and 2 critical care physicians [4%]). Five themes that represent the experiences of ACP were identified: (1) most patient consideration of values, goals, and preferences occurred outside outpatient visits; (2) optimistic attitudes from transplant teams hindered the discussions about dying; (3) clinicians primarily discussed death as a strategy for encouraging behavioral change; (4) transplant teams avoided discussing nonaggressive treatment options with patients; and (5) surrogate decision makers were unprepared for end-of-life decision-making.This study found that, despite a guarded prognosis, patients with decompensated cirrhosis had inadequate ACP throughout the trajectory of illness until the end of life. This finding may explain excessively aggressive life-sustaining treatment that patients receive at the end of life.